Metraipolis › archive › dc_7828b2b0b3a5

Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41834910
DOI
10.17179/excli2025-9096
License (as archived)
solo-consultazione
Archived
2026-11-06T10:22:17.208Z
SHA-256 of the archived text
cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01
Stable URL of this page
https://metraipolis.com/documento/dc_7828b2b0b3a5

How to cite

Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910 — Europe PMC (en), https://europepmc.org/article/MED/41834910 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7828b2b0b3a5 (Metraipolis archive dc_7828b2b0b3a5, sha256 cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01)
BibTeX
@misc{dc7828b2b0b3a5,
  title = {Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review… — Europe PMC PMID:41834910},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41834910},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7828b2b0b3a5; sha256 cfb9d30586af6dfa94f917d62bb8d8a3bfebe6ce23057800a4693c7d7cf38b01},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41834910. Agents can read the archived copy with the MCP tool read_document.